Table 2.
CTRP9 protected diabetic hearts against IR injury.
| Control | IR | IR+0.3 | IR+1 | IR+3 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 30 min | 120 min | 30 min | 120 min | 30 min | 120 min | 30 min | 120 min | 30 min | 120 min | |
| HR (bpm) | 262.1 ± 11.69∗ | 263.9 ± 8.71 | 248.6 ± 11.75 | 244.8 ± 4.98 | 266.2 ± 8.23 | 263.6 ± 13.85## | 258.4 ± 9.33 | 273.1 ± 13.90 | 268.7 ± 12.00 | 275.7 ± 14.46 |
| CF (mL/min) | 11.16 ± 0.709 | 12.64 ± 1.018 | 11.00 ± 0.640 | 7.69 ± 0.287## | 10.83 ± 0.793 | 11.27 ± 0.260##∗∗ | 10.89 ± 0.637 | 12.66 ± 0.551∗∗$ | 10.24 ± 0.852 | 12.32 ± 0.614∗∗$ |
| LVDP (mmHg) | 139.0 ± 6.81 | 135.2 ± 9.36 | 135.8 ± 4.44 | 88.4 ± 2.50## | 140.4 ± 4.76 | 93.6 ± 6.29## | 137.7 ± 6.88 | 108.3 ± 6.19#∗∗$$ | 142.7 ± 6.10 | 117.5 ± 7.11#∗∗$$ |
| +dP/dt (mmHg/sec) | 2354 ± 98.7 | 2375 ± 68.3 | 2523 ± 95.4 | 1857 ± 85.2## | 24118 ± 88.1 | 1968 ± 76.9## | 2457 ± 116.1 | 2266 ± 106.7#∗∗$$ | 2547 ± 108.0 | 2307 ± 98.7#∗∗$$ |
| −dP/dt (mmHg/sec) | −2433 ± 85.9 | −2369 ± 218.6 | −2370 ± 97.1 | −1735 ± 78.3## | −2398 ± 117.8 | −1941 ± 109.1## | −2548 ± 122.5 | −2261 ± 99.5#∗∗$$ | −2608 ± 110.5 | −2199 ± 117.5#∗∗$$ |
| RPP | 36418 ± 1014 | 35515 ± 1112 | 33487 ± 978 | 21477 ± 983## | 37244 ± 1041 | 22459 ± 996## | 35346 ± 1132 | 29484 ± 985#∗∗$$ | 38056 ± 1175 | 32177 ± 1107#∗∗$$ |
Isolated hearts from diabetic rats were subjected to IR or control protocol via a Langendorff apparatus at the presence of different dosage of globular CTRP9 (0.3, 1, and 3 μg/mL for IR+0.3, IR+1, and IR+3 groups, resp.) or equal amount of KH buffer (control), and heart rate (HR), coronary flow (CF), left ventricular developing pressure (LVDP), maximum and minimum electronically differentiated derivative of left ventricular pressure (±dP /dt) and rate-pressure product (RPP) were compared at the end of reperfusion (120 min). # p < 0.05, ## p < 0.01 versus control, ∗ p < 0.05, ∗∗ p < 0.01 versus IR, $ p < 0.05, $$ p < 0.01 versus IR+0.3, and n = 10 per group.